top of page

BIO International 2025: Germany's Aicuris, a company that focuses on helping immunocompromised patients, has breakthrough therapy designation for its HSV treatment that is in a pivotal

blonca9
Jun 17
1 min read

CEO Larry Edwards describes the unmet need in the immunocompromised space, and highlights Aicuris' commercial CMV product (PREVYMIS), partnered with Merck/MSD, and R&D products targeting HSV and BKV.

ree

Recent Posts

CREATE Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."

CREATE Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."

The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization

The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page